Cardio Diagnostics Teams Up with AGEPHA Pharma to Advance CHD Treatment with LODOCO®

Cardio Diagnostics Partnered with AGEPHA Pharma

Image Credits: Caristo

Announcement

Cardio Diagnostics Holdings Inc., a leading cardiovascular medicine company, along with its advanced technology related to AI and intersecting epigenetics, has signed an agreement with AGEPHA Pharma. The agreement will provide the required validation to the approach for the treatment of coronary heart disease (CHD). Also, AGEPHA Pharma will supply LODOCO® (low-dose colchicine) to Cardio Diagnostics for its clinical study. This drug is an FDA-approved anti-inflammatory medication that will help explore the use of cardio diagnostics PrecisionCHD™ blood test to address patients suffering from inflammation-driven coronary heart diseases and ensure asses to their response to LODOCO® by the time. This engagement will fuel the innovation and development in the healthcare market.

Efforts to Control Inflammation

Inflammation mainly targets adverse cardiac and atherosclerosis events. The clinical team is continuously exploring informative tools for appropriate guidance to various treatments and their approaches, mainly for severe conditions such as INOCA (Ischemia with no obstructive coronary arteries). This condition is highly prone to diagnostic complications and inflammatory underpinnings.

About CARDIO Diagnostics’ PrecisionCHD™

This test is an AI-influenced integrated genetic-epigenetic test, which is an addition to the management and diagnosis of CHD. The six DNA methylation markers have been evaluated by the PrecisionCHD™ test to list drivers of CHD and inflammation. For every patient, the precision test enables personalized insights consisting of their respective molecular drivers that will provide updates on new clinical decision-making and treatment. This theory and the nature of DNA methylation elevate the PrecisionCHD™ test and prove its potential in non-invasive treatment and monitoring of inflammation. It’s a win over traditional imaging-based ideas.

Currently, Cardio Diagnostics is searching for suitable clinical sites for this study. This organized study will use PrecisionCHD™ TO ADDRESS CHD patients and will prescribe them LODOCO® by a physician after clinical approval. The patients will undergo re-testing to learn changes in inflammation through DNA methylation signatures. The final study will align with the partnership with the principal investigator of the clinical site, and then will be registered as a clinical trial.

Views and Statements

Chief Medical Officer at Cardio Diagnostics, MD, PhD, Robert Philibert said, “This study is a mirror to the precision medicine model where treatment and diagnosis are guided by the patient’s molecular insights. The interventions consist of adverse events. With the help of PrecisionCHD™, most clinicians can leverage the therapeutic index of cardiovascular treatment plans for their patients.”